Cancer

Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple…

1 year ago

POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an…

1 year ago

In Shocking Reversal, CMS Wants to Allow Medicare Part D Plan Sponsors to Substitute Non-Interchangeable Biosimilars

WASHINGTON, DC / ACCESSWIRE / November 10, 2023 / On November 6, 2023, the Centers for Medicare and Medicaid Services…

1 year ago

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and…

1 year ago

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),…

1 year ago

Cantargia Publishes Interim Report for Third Quarter 2023

LUND, SWEDEN / ACCESSWIRE / November 10, 2023 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January…

1 year ago

OneMedNet Network Expands with New Partnership with Large Academic Research Medical Center to Benefit its Life Science Company Clients

~ Partnership To Leverage Real World Data for Life Science Innovation Accelerating New Diagnostic and Treatment Solutions ~MINNEAPOLIS, MN /…

1 year ago

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

- Preclinical Orders for Additional Customers Underway -STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences,…

1 year ago

Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

1 year ago